A Post Market Observational Study to Obtain Additional Information on the Use of CorMatrix® CanGaroo ECM® Envelope

Aziyo Biologics, Inc.0 个研究点开始时间: 2015年9月最近更新: 2023年7月20日

适应症

试验速览

阶段: 不适用
状态: 撤回
发起方: Aziyo Biologics, Inc.
主要终点: Device Related Adverse Events

研究概览研究设计入排标准结局指标研究者记录与标识符相似试验

研究概览

简要总结

Actively gather additional information on the use of CorMatrix CanGaroo ECM Envelope in a post market observational study.

研究设计

研究类型: Observational
观察模型: Case Control
时间视角: Prospective

入排标准

性别: All
接受健康志愿者: 否

入选标准

•Subject who has received the CorMatrix CanGaroo ECM Envelope for an implantable electronic device following battery change out or upgrade.
•Signed Informed Consent

排除标准

•Known sensitivities to porcine material.

结局指标

主要结局

Device Related Adverse Events

时间窗: 1 day post-operative follow up visit

次要结局

未报告次要终点

研究者

发起方

Aziyo Biologics, Inc.

申办方类型

Industry

责任方

Sponsor

相似试验

已完成

不适用

Obtain Additional Information on Use of CorMatrix ECM (Extracellular Matrix)Coronary Disease

NCT02073331Aziyo Biologics, Inc.1,420

已完成

不适用

A Post Market Study on the Use of Cormatrix® Cangaroo ECM® (Extracellular Matrix) EnvelopeCardiovascular Disease

NCT02530970Aziyo Biologics, Inc.1,025

已完成

不适用

Quality of Life Outcomes of HUMIRA in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) After Unsustainable Response to Biologicals and Disease Modifying Antirheumatic DrugsPsoriatic ArthritisRheumatoid ArthritisAnkylosing Spondylitis

NCT01083693Abbott162

终止

不适用

A Post Marketing Surveillance Study to Assess the Safety and Efficacy of Cetuximab Plus Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and NeckUnresectable Locally Advanced Squamous Cell Carcinoma of Head and NeckLA SCCHN

NCT01303237Merck KGaA, Darmstadt, Germany88

终止

4 期

Single Arm Post-marketing Study of SC20 ColonoscopeGentle Colonoscopy

NCT02279836Invendo Medical GmbH2